Lanso D 30

Indications:

• Healing of Erosive Esophagitis: Lanso D effectively heals all grades of erosive esophagitis (EE) for up to 8 weeks.
• Maintenance of Healed Erosive Esophagitis: It ensures sustained healing of EE and alleviates heartburn for up to 6 months.
• Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD): Lanso D provides relief from heartburn associated with symptomatic non-erosive GERD for a duration of 4 weeks.

Pharmacology:

• Lanso D, containing dexlansoprazole, a Proton Pump Inhibitor (PPI), effectively curbs gastric acid secretion by selectively inhibiting the (H+/K+)-ATPase in gastric parietal cells.
• This formulation, presented as Dual Delayed Release (DDR) capsules, ensures a two-phase plasma concentration-time profile, ensuring sustained acid suppression.

Dosage:

• Dexlansoprazole: Administer 30 mg once daily for maintaining healed erosive esophagitis and relieving heartburn.
• Dexlansoprazole MUPS (Multiple Unit Pellet System): One 30 mg tablet once daily for maintenance of healed erosive esophagitis and alleviation of heartburn.

Administration:

• Dexlansoprazole can be taken regardless of meals, either as a whole capsule or by sprinkling intact granules from the capsule onto a tablespoon, followed by immediate swallowing.

Interaction:

• Lanso D may interact with several medications such as Atazanavir, Warfarin, Tacrolimus, Clopidogrel, and Methotrexate.

Contraindications:

• It is contraindicated in individuals exhibiting hypersensitivity to any constituent of the formulation.

Side Effects:

• Common side effects include diarrhea, abdominal pain, nausea, vomiting, and flatulence.

Pregnancy & Lactation:

• Pregnancy Category B; caution is advised during pregnancy and lactation due to limited data.

Precautions & Warnings:

• Caution is warranted in patients with gastric malignancy, Clostridium difficile-associated diarrhea, bone fracture, hypomagnesemia, and those concurrently using Methotrexate.

Use in Special Populations:

• Pediatric Use: Lanso D’s safety and efficacy have not been established in children under 12 years of age.
• Geriatric Use: No dose adjustment is required for elderly patients.
• Renal Impairment: No dose modification is necessary for patients with renal impairment.
• Hepatic Impairment: Consider a maximum daily dose of Lanso D 30 mg for patients with moderate hepatic impairment.

Storage Conditions:

• Store Lanso D below 30°C in a dry place, shielded from light, and ensure it remains inaccessible to children.